Our latest press releases, media appearances and news commentary.
Medicines Discovery Catapult’s newly appointed Chief Business Officer, Dr Nicola Heron MBA sets out her intention to support up-and-coming innovators…
Ahead Of International Day Of Women And Girls In Science, Three Covid Scientists Share Their Experience of Battling the Pandemic.
Staff and students at the University of Manchester have been recognised for their role in helping to establish the Alderley Park Lighthouse Laboratory in Cheshire.
A partnership between the University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.
Scientists at the Alderley Park Lighthouse Lab in Cheshire have revealed the speed and scale at which the new variant of the COVID virus is spreading through communities across the country.
Scientists at the Alderley Park Lighthouse Lab in Cheshire processed their 6 millionth test over the festive period, the equivalent of providing tests for one in ten people in the UK.
Active Needle Technology, Xerion Healthcare and Medicines Discovery Catapult win funding to begin ground-breaking project.
Intelligent OMICS, Arctoris and Medicines Discovery Catapult test in silico pipeline for identifying new molecules for cancer treatment.
The Catapult Network launched today the 2019-2020 Annual Report – Creating the future through innovation: Recovery and Resilience.
Optibrium, Intellegens and Medicines Discovery Catapult combine their expertise in drug discovery and AI research.
See how we can help support you with your next drug discovery project.
Speak to us